Darrin Uecker Sells 20,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) CTO Darrin Uecker sold 20,000 shares of the business’s stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $16.21, for a total transaction of $324,200.00. Following the completion of the sale, the chief technology officer directly owned 122,872 shares in the company, valued at $1,991,755.12. This represents a 14.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Darrin Uecker also recently made the following trade(s):

• On Monday, September 15th, Darrin Uecker sold 25,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $15.77, for a total transaction of $394,250.00.
• On Thursday, September 11th, Darrin Uecker sold 25,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $14.78, for a total transaction of $369,500.00.

Pulse Biosciences Price Performance

Shares of NASDAQ:PLSE opened at $17.61 on Friday. The firm has a 50 day simple moving average of $15.57 and a 200 day simple moving average of $16.15. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -16.77 and a beta of 1.68. Pulse Biosciences, Inc has a one year low of $13.77 and a one year high of $25.00.

Pulse Biosciences (NASDAQ:PLSE) last announced its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02).

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets raised its holdings in Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after buying an additional 680 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after purchasing an additional 2,156 shares during the period. AlphaQuest LLC boosted its position in shares of Pulse Biosciences by 68.0% in the first quarter. AlphaQuest LLC now owns 3,116 shares of the company’s stock worth $50,000 after purchasing an additional 1,261 shares during the period. PNC Financial Services Group Inc. bought a new position in shares of Pulse Biosciences in the first quarter worth approximately $90,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Pulse Biosciences by 2,203.1% in the first quarter. GAMMA Investing LLC now owns 6,034 shares of the company’s stock worth $97,000 after buying an additional 5,772 shares in the last quarter. 76.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Oppenheimer began coverage on shares of Pulse Biosciences in a research note on Monday, July 7th. They issued an “outperform” rating and a $22.00 target price on the stock. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, Pulse Biosciences currently has a consensus rating of “Buy” and a consensus price target of $22.00.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.